Cough Relieving Medicine Brand Ranking

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. is a listed company controlled by Guangzhou Pharmaceutical Group Co., Ltd. (A shares 600332, H shares 00874), mainly engaged in: (1) Chinese and Western patent medicines, chemical raw materials, natural medicines, biomedicine, and chemical raw materials. Research, development, manufacturing and sales of intermediates; (2) Wholesale, retail and import and export business of Western medicine, Chinese medicine and medical devices; (3) R&D, production and sales of big health products; and (4) Medical services and health management , health industry investments such as health preservation and elderly care. The main traditional Chinese medicine products include Xiaoxie Pills, Qingkailing Series, Xiasangju Granules Series, Huatuo Rezai Pills, Angong Niuhuang Pills, Wanglaoji Herbal Tea, Wanglaoji Children's Qixing Tea, Zhuifeng Tougu Pills, etc.; the main chemical products include cefosthamidine , cefixime, amoxicillin, sildenafil citrate, etc.; the main health products include Wanglaoji herbal tea, Ganoderma lucidum spore oil soft capsules, etc.

Renhe (Group) Development Co., Ltd.

Renhe Pharmaceutical Co., Ltd. is a listed company listed on the Shenzhen Stock Exchange. The company's stock code is: 000650. The company's predecessor is Jiujiang Chemical Fiber Co., Ltd., which was approved by the Jiangxi Provincial People's Government in 1996. On November 18, 1996 , a company officially listed on the Shenzhen Stock Exchange with the approval of the China Securities Regulatory Commission’s Securities Regulatory Commission (1996) No. 318. In 2006, the company implemented a major asset restructuring, divested its original chemical fiber-related assets, and injected pharmaceutical assets. Through multiple share allocations, transfers, targeted share issuances, etc., the company has become Jiangxi Renhe Pharmaceutical Co., Ltd. and Jiangxi Renhe. China Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Co., Ltd., Jiangxi Heli Pharmaceutical Co., Ltd., Jiangxi Kangmei Pharmaceutical Health Products Co., Ltd., Jiangxi Pharmaceutical Durenhe Pharmaceutical Co., Ltd., Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd., Jiangxi Shining Pharmaceutical Modern pharmaceutical production and operation enterprises of many subsidiaries such as Jiangxi Ji'an Sanli Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Products Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical City Zhangshu Pharmaceutical Co., Ltd. and other subsidiaries. The company's main business: production and sales of traditional Chinese and Western medicines, raw materials and health-related products, including oral solid preparations, oral liquid preparations, large-volume injections, small-volume injections, topical lotions, liniments, suppositories, ointments and other dosage-form drugs, as well as Health-related products. The company's main products: Renhe Kelik, Youkadan series, Fuyanjie series, Dahuolou capsules, Shining eye drops, Qinghuo capsules, Zhengwei capsules, etc. Business scope is: Chinese medicinal materials planting; medicinal seedling cultivation; carton production and sales; computer software development; design, production, release, and agency of various domestic advertisements; building materials, machinery and equipment, hardware and electrical and electronic products, chemical products, Wholesale and retail of metal materials, cultural and sports office supplies, department stores. (Except for the above projects that have special provisions in the country). The company has established and consolidated a sales network covering 30 provinces, cities and autonomous regions across the country. The company adheres to the purpose of "serving human health", follows the corporate philosophy of "people-oriented and harmony-oriented", and the business philosophy of "benevolence and harmony, and win-win" and promotes the corporate spirit of "integrity and unity and keeping pace with the times". With the historical expectation of revitalizing the country's medical industry, we will go to the world and the future with new horizons and new ideas.

Sunflower Pharmaceutical Group Co., Ltd.

Kuihua Pharmaceutical Group Co., Ltd. is based on the mission of "guaranteeing the safety of Chinese children's medication, protecting the healthy growth of Chinese children. Being a good medicine for the people and bringing a healthy and beautiful life to hundreds of millions of families". It has a brand OTC product as the core and covers R&D. , well-known pharmaceutical companies in the entire industrial chain. The group was formerly the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was reorganized into a private enterprise, Heilongjiang Kuihua Pharmaceutical Co., Ltd., and then continued to grow and grew. In 2005, Kuihua Pharmaceutical Group Co., Ltd. was established. The group currently has 32 subsidiaries including 13 pharmaceutical production enterprises, 6 sales companies, 4 pharmaceutical research institutes, 2 medicinal materials planting bases, and 1 pharmaceutical packaging company. It is headquartered in Harbin City. Listed in Shenzhen at the end of 2014, with stock code: 002737. The company is currently the executive vice president unit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the vice president unit of the China Pharmaceutical Enterprise Management Association, the vice president unit of the China Pharmaceutical Business Association, the member unit of the China Traditional Chinese Medicine Association, and the vice president of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association Unit, senior vice president unit of China Over-the-counter Drug Association, etc. Kuihua Pharmaceutical Group is dominated by traditional Chinese medicine, with "chemical drugs, biological drugs" and "healthy and health products" as its two wings, and is in the six major fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, and cardiovascular and cerebrovascular diseases". It has formed a comprehensive layout of product pipelines and has a rich product line, with a total of 21 dosage forms, 257 products in production, and 1,126 drug approval numbers. Among them, nearly 100 children's medicine approval numbers have been held and more than 60 sold drug products. Xiao Kuihua Children's Medicine has unshakable advantages in the same category in the OTC field in terms of "sales scale, product quantity, and scale single products". . The company is an OTC large-scale enterprise with "dual brand umbrellas". "Sunflower" and "Little Sunflower" have built the consumer trust foundation for the company's adult medicine and children's medicine. After more than 20 years of creation, the company has adopted the combination marketing model of "brand model, general medicine model, prescription model, big health model, new retail model" and other combination marketing models to build a unique combination marketing and full model in the industry. The integration model has attracted attention and imitation in the industry.

Yabao Pharmaceutical Group Co., Ltd.

In 1992, Ding Gui launched a concentrated herbal essence, which was a small piece of Ding Guier navel patch. The German advanced plant extraction technology is used to extract Chinese herbal essences and use umbilical therapy to treat the baby's belly. Applying the belly button to cure diarrhea, you don’t have to worry about side effects, and save the trouble of feeding medicine. The patch is skin-friendly and breathable, and strives to give your baby a comfortable feeling of delicate skin. Safe and effective, use a suitable method to solve the baby's diarrhea problem. In 2016, Ding Gui launched the Jetsuya Gel, a professional Chinese medicine spleen-strengthening product in China. Choose seven medicines with the same origin as medicine and food to strengthen the spleen and eliminate dampness, treat both symptoms and root causes, and solve the problem of spleen deficiency in your baby. The fruit puree is made in the form of sour and sweet, it does not look like medicine, and it does not taste like medicine; it is safe and effective, and uses a baby's easy-to-accept method to solve the problem of baby not eating. In 2003, Ding Gui launched an oral solution of zinc gluconate for children to supplement important trace elements in the growth and development of the baby. We also studied the zinc supplement standards of the Chinese Nutrition Society, and supplement different amounts at different ages to avoid insufficient amounts and excessive amounts.

China Resources Pharmaceutical Holdings Co., Ltd.

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of ​​"inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.

Hainan Calabash Kids Pharmaceutical Group Co., Ltd.

Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine. The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies. At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years. Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!

Zhuhai United Laboratories Co., Ltd.

Federal Pharmaceutical was founded in 1990 and listed in Hong Kong in 2007. The stock code is 3933.HK, mainly engaged in the research and development, production and sales of drugs. After more than 30 years of development, Federal Pharmaceutical has formed a comprehensive pharmaceutical group with four major business segments: preparations, raw materials, biology, and animal welfare, and nine production and R&D entities. Its sales network covers the world and currently has more than 16,000 employees. Since its establishment, Federal Pharmaceuticals has been committed to providing high-quality products and services to the society and promoting high-quality development of the pharmaceutical industry. It is one of the leading comprehensive pharmaceutical companies in China. Zhuhai Federal Pharmaceutical Co., Ltd. was registered and established in 1993. The factory was completed and put into production in 1998. Currently, production bases have been established in Sanzao Town and Nanshui Town, Jinwan District, Zhuhai City, covering a total area of ​​450,000 square meters and employees are about 2,700. people. After more than 20 years of development, it has become a high-tech modern comprehensive pharmaceutical enterprise integrating production and R&D. The company's main products include more than 50 varieties of insulin, penicillin, cephalosporin, carat, and penem. Oral semi-synthetic penicillin workshop is currently a production workshop with a large production capacity of similar products in China, with an annual production capacity of more than 5,000 tons. The annual production capacity of the "Golden Feiyan" and "Silver Feiyan" brand products of the cephalosporin series and the carat series are about 1,000 tons. Products sold worldwide. Federal Pharmaceuticals is a company that uses genetically engineered Pichia cerevisia expression technology to produce insulin products, and is also a company that has an insulin prefilled pen assembly line in China. In 2009, the second generation of insulin human insulin (Yusling) was launched. In 2016, the third generation of insulin analog insulin glargine (Yusling) was launched. In 2021, the insulin aspart was launched, and Federal Pharmaceutical became the same. Domestic companies with second and third generation insulin production capabilities. After the project reaches full production, the production capacity will reach 3 tons of raw materials and 300 million preparations, with an annual output value of more than 10 billion yuan. Introducing intelligent manufacturing, Zhuhai Company is an enterprise that adds sterile operation robot intervention system to the sterile raw material industry. It uses robots instead of manual operation in A-level clean areas to ensure the quality of sterile drugs and reduce safety risks. The explored intelligent manufacturing has a profound impact on the quality assurance of sterile pharmaceuticals and the application of industrial intelligence. Taking a diversified development path, Federal Peptide Beauty is a company that has created a polypeptide cosmetic raw material brand for skin care. Its main effects include whitening, firming, anti-wrinkle and anti-aging. In 2017, the use of peptide raw materials into finished cosmetics began, opening a new era of federal peptide beauty skin care. In line with the international level, the quality system insists on international capacity building, and Zhuhai Company always puts quality work first. All series of products such as insulin and antibiotics have passed the domestic GMP compliance test. Amoxicillin and ampicillin raw materials have been subjected to German GMP certification inspections many times. Amoxicillin sodium, potassium clavulanate and other sterile raw materials have obtained the EU CEP certificate, and sterile raw materials such as ampicillin sodium and sulbactam sodium Together, we have successively passed the official joint GMP inspections of EDQM and Spain and other officials. In the future, Federal Pharmaceutical will continue to promote industrial upgrading and innovative development, develop more safe and effective drugs, and make greater contributions to human health.

Teiyi Pharmaceutical Group Co., Ltd.

Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Teyi Pharmaceutical) is a pharmaceutical listed company (stock code 002728) integrating pharmaceutical research and development, pharmaceutical industry, and pharmaceutical commerce. Its subordinate enterprises are distributed in Guangdong, Hainan, Anhui and other regions. Teyi Pharmaceutical and its wholly-owned subsidiary Hainan Haili Pharmaceutical Co., Ltd. and Taishan Xinning Pharmaceutical Co., Ltd. are both national high-tech enterprises. Teyi Pharmaceutical has been successively rated as "Outstanding Contributor Enterprise in the Pharmaceutical Industry in Guangdong Province", "Netherlands Science and Technology Enterprise in Guangdong Province", "Netherlands Innovation Industrialization Demonstration Base", "Netherlands Innovation Enterprise in Guangdong Province", and "Abide by Contracts and Harmony Credit enterprises", "A-level taxpayer", "AA-level credit-grade customer", etc.; Hainan Haili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Teyi Pharmaceutical, has been successively rated as "National Intellectual Property Advantage Enterprise in 2018" and "Hainan Leading enterprises in the industrial industry (Chinese patent medicine manufacturing industry)", "national quality, service, and reputation AAA enterprises" and "A-level taxpayers", etc. Teyi Pharmaceutical industry includes Taishan pharmaceutical production base (formerly Guangdong Taicheng Pharmaceutical), Haikou pharmaceutical production base (Hainan Haili Pharmaceutical Co., Ltd.), raw material pharmaceutical production base (Taishan Xinning Pharmaceutical Co., Ltd.) and chemical product production base (Taishan Chemical Factory Co., Ltd.). Teyi Pharmaceutical Group's products include Chinese patent medicines, chemical preparations, chemical raw materials and chemical products. Among them, the "Special One" brand series covers cough and phlegm relief, kidney nourishment, anti-infection, cardiovascular and cerebrovascular and digestive system medications, among which the main preparation products include cough and anti-inflammatory tablets, Pudilan anti-inflammatory tablets, Xuesaitong dispersed tablets, Yixinshu Granules, Ginkgo Leaf Dispersion Tablets, Jinkui Shen Qi Tablets, Magnesium Aluminum Carbonate Chewable Tablets, Erythromycin Enteric Coated Tablets, Erythromycin Tablets, Rorythromycin Capsules, Amoxicillin Capsules, Omeprazole Enteric-coated capsules, etc.; the main chemical raw materials and chemical products include magnesium aluminum carbonate, sodium phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. Teyi Pharmaceutical's core product is cough-relieving tablets. Its secret recipe was included in the Lingnan Traditional Chinese Medicine Cultural Heritage Protection List (the first batch) in 2009 and was recognized as a key new product in Guangdong Province in 2012; a wholly-owned subsidiary Taishan Xinning Pharmaceutical The key products produced by the Co., Ltd. are magnesium aluminum carbonate, sodium phenytoin, glacial acetic acid, calcium chloride and other raw materials, and are ranked among the top in the national market share. Sodium chloride for injection and bismuth nitrate for basic use have been awarded the "National Medical Administration's high-quality product". In 2018, Teyi Pharmaceutical added pills and eye drops through asset acquisition. The main varieties of pills include Xuedu Pills, Xiaozhu Pills, Tongmai Zhanzhi Pills, Ruyi Dingpan Pills, Wulin Pills, Anti-Tube Pills, Menstrual Freckle Pills, etc. The main products of eye drops include compound dextran 70 eye drops wait. At the same time, the original product combination has also been enriched, such as the respiratory system, including Pudilan anti-inflammatory tablets, Hanhuangling Granules, Xiqingguo Granules, etc., the digestive system, Fengliao Intestine Weakang Tablets, etc., and Zhuangyao Jianshen Pills in Buyi. , Bushen Banlong Capsules, etc. have improved the segmentation of the product line for Teyi Pharmaceutical and also provided guarantees for the segmentation and refined promotion of sales channels. Teyi Pharmaceutical Group currently has two nationwide sales and commercial platforms, among which Guangdong Teyi Haili Pharmaceutical Co., Ltd. operates the "Teyi" brand series produced by Teyi Pharmaceutical Industry. Another commercial platform is Hainan Haili Doctor Pharmaceutical Group Co., Ltd., which operates OEM products of the "Haili Doctor" brand and adopts regional agency sales across the country, including Chinese patent medicines and chemical preparations, and is also diversified by Teyi Pharmaceutical. , an important support for the development of professional value-added business direction. In the future, Teyi Pharmaceutical will continue to adhere to the corporate purpose of "focusing on quality, strengthening R&D, and sustainable development", with endogenous growth as the core and external growth as the auxiliary, strengthen resource integration and internal potential tapping, and strive to build excellent brands and maintain the enterprise. and become a competitive pharmaceutical company.

Sichuan Fengchun Pharmaceutical Co., Ltd.

Sichuan Fengchun Pharmaceutical Co., Ltd. (abbreviated as Fengchun/Fengchun Pharmaceutical) was founded in 1973 and completed its strategic restructuring in 2000 after the restructuring of the former Zhongjiang Pharmaceutical Factory. Now, a modern private enterprise has been formed that integrates pharmaceutical research, industrial production, pharmaceutical sales, agricultural breeding, big health industry, and project investment. As a long-standing pharmaceutical company in Kawachi, it has been devoted to inheriting the innovative development of traditional Chinese medicine and modern medicine. At present, it has 4 GMP production factories (including well-known subsidiaries such as Jiuzhaigou Natural Pharmaceutical and Sichuan Shenghe Pharmaceutical); more than 20 breeding companies; more than 5,000 employees; the company, wholly-owned subsidiaries and shareholders have assets of nearly 30 RMB 100 million; more than 1,500 mu of industrial land, with an industrial construction area of ​​more than 330,000 square meters; more than 230,000 mu of GAP planting land, forestry and aquaculture land. In 2014, Fengchun acquired Jiuzhaigou Natural Pharmaceutical Co., Ltd. and its four wholly-owned subsidiaries; in early 2020, Fengchun Holdings Sichuan Shenghe Pharmaceutical Co., Ltd. and its two wholly-owned subsidiaries: 2021 Sichuan Fengchuntang Chinese Medicine Decoction Co., Ltd. was established in 2022 and passed the GMP certification, committed to creating Chinese medicine fine decoctions. At this point, Fengchun has taken solid steps in building a traditional Chinese and Western medicine industry with domestic first-class R&D capabilities, extremely large production scale and characteristics, as well as the Qiang and Tibetan ethnic pharmaceutical industries. At present, its pharmaceutical companies have 114 invention patents and 403 drug production approval documents. In order to sustainable protection and utilization of scarce traditional Chinese medicine resources, its Sichuan Fengchun Musk Industry Group has been established and approved 13 artificially bred forest musk and horse musk subsidiaries, and another 7 are under construction. Jiuzhaigou Natural Pharmaceutical Co., Ltd., a subsidiary, is one of more than 10 pharmaceutical companies approved to use natural musk in China recently, and is also a pharmaceutical company approved to use natural musk as a drug product in China.

Jiuzhaigou Natural Pharmaceutical Co., Ltd.

Jiuzhaigou Natural Pharmaceutical Co., Ltd. is a national designated manufacturer of national national medicines, a science and technology innovation enterprise in Sichuan Province, and is currently a wholly-owned subsidiary of Sichuan Fengchun Pharmaceutical Group. Jiuyao’s predecessor was Aba Prefecture Pharmaceutical Factory in Sichuan Province. It was founded in 1970. Over the years, the company has based on resource advantages and relying on technological progress, and its scale and strength have been continuously growing. The company makes full use of the unique medicinal resources of "Snow Mountain Grassland" to develop and produce 59 Chinese and Tibetan patent medicines and Western medicines in 11 dosage forms. Varieties such as "獐子子" and "Jiuzhaigou" brand Xiaojin Wan, Xihuang Wan, Niuhuang Xingxiao Wan have won various awards from the state and provincial levels. Chuanbei Sydney Pear Paste, Wuwei Musk Pills, Xiao Chaihu Tablets, and Lianpu Shuangqing Tablets have successively been followed. It was rated as a national protected variety of traditional Chinese medicine; the company was shortlisted in the top 30 large-scale pharmaceutical industry enterprises in Sichuan in 1997, with a large market share of the top 30, etc. In 2008, the company's Yingxiu production base was destroyed during the "May 12" Wenchuan earthquake. Jiuyao people rushed to produce and save themselves in the face of disasters and grief. At present, the Xuankou production base and Jiuyao Deyang Branch have been built.

Chongqing Taiji Industry (Group) Co., Ltd.

Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees. In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs. The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people. Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.

Guangzhou Xiangxue Pharmaceutical Co., Ltd.

Guangzhou Xiangxue Pharmaceutical Co., Ltd. was established in 1997 and was listed on the Shenzhen Stock Exchange GEM in 2010 (stock code: 300147). The company regards the development of traditional Chinese medicine and the realization of traditional Chinese medicine modernization as its long-term development strategy. It has now become a leading Chinese medicine modernization enterprise and high-tech enterprise with independent intellectual property rights, independent brands and independent innovation capabilities, focusing on new Chinese herbal medicines, Chinese patent medicines, functional health products, The big health industry in the fields of biomedical engineering, life science research, etc. has successively established more than 60 subsidiaries in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, and invested in the construction of large-scale GMP production bases and GAPs. Medicinal materials planting bases will create a complete industrial chain of traditional Chinese medicine resource development, new drug research and development and creation, advanced traditional Chinese medicine manufacturing, and modern logistics and distribution, and form integrated innovation of the entire industrial chain.

Kunming Traditional Chinese Medicine Factory Co., Ltd.

Kun Chinese Medicine started in the 14th year of Hongwu (1381) of Taizu of the Ming Dynasty and officially started construction in the 6th year of Daoguang (1826) of the Qing Dynasty. It has a history of more than 600 years! The company's full name is "Kunming Traditional Chinese Medicine Factory Co., Ltd.", and is a "Chinese time-honored brand" enterprise, a national intangible cultural heritage protection unit, a high-tech enterprise, an Yunnan Enterprise Technology Center, etc. Kun Chinese Medicine is a benchmark enterprise in my country's traditional Chinese medicine industry and represents the development level of advanced traditional Chinese medicine enterprises. Over the past 600 years, the wind and rain have been blowing, spring and autumn fruits have been flourishing. Generations of Kunming Chinese Medicine people have adhered to the spirit of "no reduction and no roughness to cultivate high-quality products, diligent and hardworking, and will be healthy", worked hard, made continuous progress, actively sought, and developed steadily, and achieved remarkable results. Achievements. Kun Chinese Medicine Majinpu production base covers an area of ​​172 mu, designed with the concept of green, environmentally friendly, energy-saving, simplicity and modernity, and introduced intelligent quality testing equipment and traditional Chinese medicine production equipment, with tablets, pills, granules, capsules, 10 dosage forms including powder, syrup, liniment, wine, paste, and mixture, covering the pretreatment, preparation, outsourcing production line and decoction production line of traditional Chinese medicine production. All of them have passed the national GMP certification and realized the traditional Chinese medicine extraction production line and traditional Chinese medicine plastics. Intelligent control of production lines, packaging connections, logistics and other processes. At present, Kun Chinese Medicine is focusing on the vision of "casting high-quality Chinese medicine and serving healthy life", adheres to the mission of "big medicine is virtuous, and sting is embraced", takes customer service as the basis and value sales as the orientation, and actively implements the "big C model". By reaching a "big consensus" with major chains, entering the TOP chain, carrying out "big drainage", "big training", "big detonation" and "big membership", creating core single-product Shenling Jianpiwei Granules, and opening a new spleen-tonifying new The brand potential of the times. Kunming Chinese medicine products have always been well-known in Southeast Asian countries. Many products of Shugan Granules, Qingfei Huatan Pills, Killing Pills, Gastrodia ejaculation pills, and Gastrodia ejaculation and Wind Replenishment Pills have been successfully registered in Vietnam, Singapore, Indonesia and other countries. Kunming Chinese Medicine has been passed down for a century, with a rich history, unique products and excellent quality. "Quality Kunming Chinese Medicine" is a lofty reputation and brand recognition given by consumers. Kun Chinese Medicine has always developed a large number of advantageous varieties with its unique resources, technology, equipment, talents and network advantages, including Shenling Jianpiwei Granules, Shugan Granules, Oropharyngeal Qingwan, Qingfei Huatan Pills, Banlan Qingre Granules, cold anti-inflammatory tablets, cough pills, Nuanwei Shule granules and other medicines.

King To Nin Jiom Medicine Manufactory Co., Ltd.

Since its establishment in 1946, Kyoto Nianci An has been producing the century-old Milian Chuanbei loquat paste, and has been expanding continuously during this period. It has now become one of the manufacturers leading the development of Chinese patent medicines in Hong Kong. The natural Chinese herbal medicine products produced are sold well. Globally renowned. In order to cooperate with the demand for natural Chinese herbal products outside Hong Kong and even around the world, Kyoto Nianci'an will develop a series of convenient and effective herbal products to fundamentally help customers by combining advanced technology and strict quality control, combining extensive traditional Chinese herbal knowledge. Solve various physical discomfort symptoms, whether it is colds, throat pain, cough and sticky phlegm, heat and heat, menstrual pain and discomfort, or even acne.

Jilin Wutai Gankang Pharmaceutical Co., Ltd.

Jilin Wutai Pharmaceutical Group Co., Ltd. is a well-known pharmaceutical enterprise group in China. Since the 1980s, it has entered the business world, pioneering and enterprising, and operates honestly, and has gradually developed into a combination of pharmaceutical production, scientific research and development, wholesale and retail, real estate development, healthy food production and development. A powerful enterprise group that integrates diversified operations across industries. Boy Excellence: The group owns many wholly-owned subsidiaries including Jilin Wutaigankang Pharmaceutical Co., Ltd., Jilin Wutaigankang Pharmaceutical Co., Ltd., and Jilin Northern Pharmaceutical Co., Ltd. The company's sales network covers more than 100 large and medium-sized cities across the country. So far, Gankang® product sales cover nearly 520,000 retail pharmacies, community service stations, etc., and the product sales have hit new highs in a row. The company now has more than 2,000 employees, including more than 50 senior management personnel and more than 80 senior scientific researchers. It has played its talents under the employment mechanism of the company's "goodness is like water, follow the trend, people-oriented, and burst out potential" to develop with the company. The group has adhered to the corporate spirit of "loyalty, tenacity, diligence and persistence" for many years, focused on the production and research and development of drugs, upholding a rigorous craftsmanship style, and is committed to becoming a leading enterprise in the field of medicine and health in my country. Keep improving and moving forward: The group currently has two pharmaceutical production bases, and its strong production capacity has laid a solid foundation for the development of the group and the production of medicines. "Gankang" production base - Jilin Wutai Gankang Pharmaceutical Co., Ltd. is located in Changchun Economic and Technological Development Zone. It was established in September 1999 with a total investment of RMB 120 million and covers an area of ​​more than 60,000 square meters. The construction area is about 16,000 square meters, and it has many internationally advanced production lines, with an annual production capacity (single shift) of 1 billion tablets and 300 million capsules. In 2002, it was the first to pass the national GMP pharmaceutical manufacturer certification at one time. Since 2008, it has been recognized as a "high-tech enterprise" for many consecutive times. "Wu Tai" pharyngitis tablet production base - Jilin Wu Tai Gankang Pharmaceutical Co., Ltd. is located on the beautiful Songhua River. It completed the relocation of the old site and the construction of the factory in the end of 2003. The total investment is RMB 80 million and covers an area of ​​RMB 100 million. More than 50,000 square meters, and passed the national GMP certification in 2004 and the new version of GMP certification in 2014. It now has 12 production lines including tablets, capsules, ointments, oral liquids, granules, and Chinese patent medicines, with more than 50 varieties. It is a pharmaceutical production base with international advanced production levels. In 2020, Wutai Pharmaceutical Industrial Park located in Xinglongshan Free Trade Zone in Changchun was officially opened. Phase I of the Industrial Park covers an area of ​​about 100,000 square meters, with a total construction area of ​​750,000 square meters. 100 million yuan is invested to introduce advanced equipment and realize dedicated line production; it now has a modern comprehensive preparation workshop, a dedicated energy power center, and a smart logistics warehouse Six functional centers, including the center, sewage treatment station, comprehensive quality inspection office building, and leisure service center, are committed to building a first-class domestic pharmaceutical industry complex. The second phase of Wutai Pharmaceutical Industrial Park, with a planned building area of ​​150,000 square meters, mainly focusing on traditional Chinese medicine production, including preparation building, R&D center, traditional Chinese medicine extraction workshop, pilot workshop, office building and related supporting facilities. It has the most production capacity in Jilin Province. Large traditional Chinese medicine production workshop. After reaching full capacity, the annual total output value is expected to be 3 billion yuan, and the annual profit and tax can reach 500 million yuan. After all the first and second phases of the project are put into production, the annual total output value can reach 5 billion yuan and the total profit and tax will reach 1 billion yuan, which will become a modern pharmaceutical production base with international standards.

Sichuan Taihuatang Pharmaceutical Co., Ltd.

Sichuan Taihuatang Pharmaceutical Co., Ltd. was founded in 1988 and is a modern pharmaceutical enterprise under the Sichuan Natural Resources Investment Group. Over the years, Taihuatang has always adhered to the spirit of "two bombs and one satellite", and has taken "leading modern science and technology and promoting traditional Chinese medicine culture" as its corporate mission, striving for excellence and developing distinctively. The company now covers an area of ​​nearly 200 mu and has more than 1,000 employees. It has 8 national GMP production lines including capsules, tablets, oral liquids, and 82 products. The products involve multiple treatment areas such as nourishing and replenishing the body, digestive system, cardiovascular and cerebrovascular, tumor auxiliary drugs, gynecological drugs, antibiotics, antipyretic and analgesic drugs. The company is currently a high-tech enterprise in Sichuan Province and an independent intellectual property advantage enterprise in Sichuan Province.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Guangzhou Baiyunshan Hutchison Huangpu Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Huangpu") was jointly established in May 2005 by the Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group and Hutchison Huangpu (China) Company, a subsidiary of Mr. Li Ka-shing. The joint venture was formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory. It was established in May 1988. It was derived from the farm operation area established in 1956 and was transformed into a tonic factory that combines agriculture and industry, and then transformed into Guangzhou Baiyun, which operates the pharmaceutical and health industry. Shan Chinese Medicine Factory. The company stands at the forefront of the times and the height of the industry, takes the cross policy of "education, love, technology, innovation, responsibility" as a guide, and takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine" as its mission, and takes economic benefits. As the center, we focus on management internally, expand the market externally, and implement the three major strategies of "talent, brand, and technology", forming five core competitive advantages: scientific and technological innovation, responsible marketing, cultural heritage, talent engineering, and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, collection, output value and profit maintained a growth of more than 30%. The company actively builds a pioneer modern Chinese medicine enterprise and enters into advantageous enterprises in the big health industry.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Guangzhou Baiyunshan Pan Gaoshou Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyunshan Pan Gaoshou") was founded in the 16th year of Guangxu in the Qing Dynasty (1890 AD) and is a "time-old Chinese brand". It is currently affiliated to Guangzhou Pharmaceutical Group Co., Ltd., and is a modern high-tech enterprise known for the research and development and production of Chinese patent medicines for relieving cough and phlegm. "Pan Gaoshou" was co-founded by the brothers Pan Baishi and Pan Yingshi from Kaiping, Guangdong. It was originally named "Changchundong Pan Gaoshou" pharmacy. In 1935, Pan Yusheng, the son of Pan Baishi, first created the "Chuanbei Loquat Lu in 1956, and the "Public-private joint venture Pan Gaoshou Joint Pharmaceutical Factory" was established. In 1980, the name of "Guangzhou Traditional Chinese Medicine Factory Seven" was abolished during the Cultural Revolution and the name of "Guangzhou Pan Gaoshou Pharmaceutical Factory" was restored. No. In 1993, the pharmaceutical factory was reorganized into "Guangzhou Pangaoshou Pharmaceutical Co., Ltd.". In 2012, it was renamed as "Guangzhou Baiyunshan Pangaoshou Pharmaceutical Co., Ltd.". Baiyun Mountain Pan Gaoshou is located at No. 9-11 Tianbao Road, Donghuan Street, Panyu District, Guangzhou. It covers an area of ​​more than 50,000 square meters, has a construction area of ​​80,000 square meters, and has a greening area of ​​80%. It is a modern pharmaceutical manufacturing built in accordance with national GMP standards. enterprise. The existing production equipment configuration has reached the advanced domestic and international level, and a complete set of quality management systems have been established. Baiyunshan Pan Gaoshou mainly produces traditional Chinese medicine preparations, and has a product series covering four major fields, including respiratory, pediatrics, gynecology/oncology, health food, and more than 40 varieties of 5 major dosage forms. "Cough treatment for a hundred years, real material", Chuanbei loquat dew is the first in China. It is the company's four pillar products, including snake gallbladder Chuanbei liquid, snake gallbladder Chuanbei loquat paste, and honey-refined Chuanbei loquat paste. They are all Guangdong Province. "High-tech products", among which the cough-treated Sichuan Loquat Dew and honey-refined Sichuan Loquat Paste are the exclusive varieties in China. Xingsu cough relief oral liquid, yin-clearing lung mixture, Pinellia syrup, Sangju cold mixture, etc., pediatric medicines for children, Qingreli lung oral liquid, Clear heat and moisture oral liquid, Qixing Tea Syrup, etc., Gynecology The medicine Danbi Capsules, Ginseng Shuo Shuo Shuo, Yipu products, and many other categories are popular among consumers. The subsidiary Guangzhou Pan Gaoshou Natural Health Products Company mainly produces Sichuan loquat sugar, throat lozenges, turtle jelly, herbal tea and other foods and health foods, so as to achieve the "two-wings flying" of medicines and food.

Harbin Kanglong Pharmaceutical Co., Ltd.

Harbin Kanglong Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Harbin Liming High-tech Development Zone. The factory area covers an area of ​​nearly 100,000 square meters. After years of hard work, it has now developed into a high-tech pharmaceutical company integrating R&D, production and sales. The enterprises are highly recognized by the state, provincial and municipal governments and have become the weather vane for modern and innovative traditional Chinese medicine enterprises. The company's main products are sugar-free powerful loquat deer, concentrated pediatric cough-styrene oral liquid and Yanning syrup, all of which are varieties that combine multiple patents. Among them, the main product, sugar-free powerful loquat deer, is a national basic drug and national medical insurance variety. Building a modern high-tech traditional Chinese medicine industry is Kanglong Pharmaceutical's pursuit, and inheriting and innovating, developing and promoting traditional Chinese medicine culture is the responsibility and responsibility of enterprises to society. Kanglong Pharmaceutical actively participates in the reform and development of my country's health field, devotes itself to the big health industry, and focuses on the research of advanced technologies, pursues conscientious quality, and comprehensive modern management. While focusing on the innovative development and protection of traditional Chinese patent medicines, Kanglong Pharmaceutical has continuously broadened its industry boundaries, explored the future of the industry, and provided people with a variety of life and health services. Over the years, Kanglong Pharmaceutical has adhered to the strategic plan of "quality survival, integrity development, brand market, and international pharmaceutical companies", continuously deepened reforms, innovation and change, won the trust of consumers and won the same industry. wide recognition. Harbin Kanglong Pharmaceutical Co., Ltd. is leading the same industry to face the Chaoyang and moving towards a higher and stronger field of medicine.

Reckitt Benckiser

Strepsils offers soothing lozenges for sore throats and coughs, providing quick and effective relief.